½ÃÀ庸°í¼­
»óǰÄÚµå
1363098

OTC ¾È±¸°ÇÁ¶Áõ¿ë Á¡¾È¾à ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : À¯Çüº°, Á¦Ç° À¯Çüº°, Á¡µµº°, À¯Åë ä³Îº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2023-2030³â)

OTC Dry Eye Drops Market Size, Share & Trends Analysis Report By Type (Branded, Generics), By Product Type (With Preservatives, Preservative Free), By Viscosity (Low, High), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 130 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

OTC ¾È±¸°ÇÁ¶Áõ¿ë Á¡¾È¾à ½ÃÀå ¼ºÀå ¹× µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é OTC ¾È±¸°ÇÁ¶Áõ¿ë Á¡¾È¾à ¼¼°è ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 60¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇϰí 2023³âºÎÅÍ 2030³â±îÁö 7.70%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.

½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¾È±¸°ÇÁ¶Áõ À¯º´·ü Áõ°¡, ½º¸¶Æ®Æù, ÄÄÇ»ÅÍ µî µðÁöÅÐ ±â±âÀÇ º¸±ÞÀ¸·Î ÀÎÇÑ ½Ã·Â ºÎ´ã Áõ°¡, Àü ¼¼°è °í·ÉÈ­ Àα¸ÀÇ Áõ°¡ µîÀÔ´Ï´Ù.

°Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ´« °Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Á¦Ç° ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àü ¼¼°è 7¾ï 5,000¸¸ ¸í ÀÌ»óÀÌ ¾È±¸°ÇÁ¶Áõ Áõ»ó°ú ÀÓ»óÀû ¡Èĸ¦ ¸ðµÎ °¡Áö°í ÀÖ´Â ¹Ý¸é, 6¾ï ¸í ÀÌ»óÀÌ ÀÓ»óÀû ¡ÈÄ´Â ÀÖÁö¸¸ Áõ»óÀÌ ¾ø¾î ¾È±¸°ÇÁ¶Áõ(DED) ¹ßº´ À§Çè¿¡ ³ëÃâµÇ¾î ÀÖ°í, ¾È±¸°ÇÁ¶Áõ Áõ»óÀÌ ÀÖÁö¸¸ ÀÓ»óÀû ¡Èİ¡ ¾ø´Â Àα¸´Â ¾à 14¾ï ¸í¿¡ ´ÞÇϱ⠶§¹®¿¡ OTC ¾È±¸°ÇÁ¶Áõ Á¡¾ÈÁ¦ ½ÃÀå ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, µµ½ÃÈ­¿Í Çö´ëÀÎÀÇ »ýȰ¹æ½ÄÀº ¾È±¸°ÇÁ¶Áõ ¹ßº´·üÀ» ³ôÀ̴µ¥ ÀÏÁ¶Çϰí ÀÖ½À´Ï´Ù. µµ½Ã »ýȰ¿¡ µû¸¥ Àå½Ã°£ÀÇ ½ºÅ©¸° »ç¿ëÀº ´« ±ôºýÀÓ È½¼öÀÇ °¨¼Ò¿Í ´«¹°¸·ÀÇ ÆÄ±«¸¦ ÃÊ·¡Çϰí, µµ½Ã ȯ°æ ¿À¿° ¹°ÁúÀº ½Ã·ÂÀ» ÀÚ±ØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àå½Ã°£ÀÇ ÃâÅð±Ù°ú ºÒ±ÔÄ¢ÇÑ ¼ö¸é ÆÐÅÏÀ» Æ÷ÇÔÇÑ µµ½Ã »ýȰÀÇ ´Ù¾çÇÑ ½ºÆ®·¹½º ¿äÀÎÀÌ ´«¹° ºÐºñ¿Í ´«ÀÇ Àü¹ÝÀûÀÎ Æí¾ÈÇÔ¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÄ OTC ¾È±¸°ÇÁ¶Áõ¿ë Á¡¾È¾à ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ÁøÀÔ ±â¾÷µéÀº ¼¼°è »ç¾÷ È®Àå ¹× Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ È®´ëÇϱâ À§ÇØ °è¾à, ÀμöÇÕº´, Á¦ÈÞ, Ãâ½Ã µî ´Ù¾çÇÑ Àü·«À» ±¸»çÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, AlconÀº 2022³â 1¿ù À¯·´¿¡¼­ Systane Complete Preservative-Free Lubricant Eye Drops¸¦ Ãâ½ÃÇÏ¸ç ±Þ¼ºÀåÇϰí ÀÖ´Â ¹«¹æºÎÁ¦ Á¡¾ÈÁ¦ Ä«Å×°í¸®¿¡¼­ »ç¾÷ È®ÀåÀ» ²ÒÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, 2023³â 7¿ù¿¡´Â TheaLipid°¡ Thea Pharmaceuticals¿¡¼­ DED Ä¡·áÁ¦·Î Ãâ½ÃµÇ¾î ȸ»çÀÇ È®Àå °èȹ¿¡ ÈûÀ» ½Ç¾îÁÖ°í ÀÖ½À´Ï´Ù.

OTC ¾È±¸°ÇÁ¶Áõ¿ë Á¡¾È¾à ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®:

  • Á¦Ç° À¯Çüº°·Î´Â Á¦³×¸¯ ÀǾàǰÀÌ 2022³â ½ÃÀå¿¡¼­ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, Á¦³×¸¯ ÀǾàǰÀÇ ³ôÀº ºñ¿ë È¿À²¼ºÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • Á¦Ç° À¯Çüº°·Î´Â ¹æºÎÁ¦ ºÎ¹®ÀÌ 2022³â °¡Àå Å« ½ÃÀå ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ±ä º¸Á¸ ±â°£°ú ½¬¿î º¸°üÀÌ ÀÌ ºÎ¹®ÀÇ ¼ºÀå¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.
  • Á¡µµ Ãø¸é¿¡¼­´Â ÀúÁ¡µµ ºÎ¹®ÀÌ 2022³â ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. Àû¿ëÀÇ ¿ëÀ̼º°ú ºü¸¥ ¿ÏÈ­°¡ ÇâÈÄ ¸î ³â µ¿¾È ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • À¯Åë ä³Îº°·Î´Â ¼Ò¸Å ¾à±¹ ºÎ¹®ÀÌ 2022³â ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù. ±× ÀÌÀ¯´Â Á¢±Ù¼º°ú ÆíÀǼºÀ¸·Î ÀÎÇØ ¼ÒºñÀÚµéÀÌ ¾È±¸°ÇÁ¶Áõ ¾È¾à°ú °°Àº OTC Á¦Ç°À» ½±°Ô ±¸¸ÅÇÒ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù.
  • ºÏ¹Ì Áö¿ªÀº 2022³â °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â °ÍÀº Àß ¾Ë·ÁÁø ½ÃÀå ±â¾÷ÀÇ Á¸Àç, Å©°í ´Ù¾çÇÑ È¯ÀÚÃþ, ¾È±¸°ÇÁ¶Áõ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ÀÇ Áõ°¡·Î ÀÎÇØ ÀÌ Áö¿ªÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óºÎ ½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå µ¿Çâ°ú Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • »ç¾÷ ȯ°æ ºÐ¼®
    • PESTLE ºÐ¼®
    • Porter's Five Forces ºÐ¼®
  • COVID-19 °¨¿°ÁõÀÇ ¿µÇ⠺м®

Á¦4Àå À¯Çüº° ºñÁö´Ï½º ºÐ¼®

  • OTC ¾È±¸°ÇÁ¶Áõ¿ë Á¡¾È¾à ½ÃÀå : À¯Çü º¯µ¿ ºÐ¼®, 2022³â ¹× 2030³â
  • ºê·£µå
  • Á¦³×¸¯

Á¦5Àå Á¦Ç° À¯Çüº° ºñÁö´Ï½º ºÐ¼®

  • OTC ¾È±¸°ÇÁ¶Áõ¿ë Á¡¾È¾à ½ÃÀå : Á¦Ç° À¯Çü º¯µ¿ ºÐ¼®, 2022³â ¹× 2030³â
  • ¹æºÎÁ¦ »ç¿ë
  • ¹æºÎÁ¦ ¹Ì»ç¿ë

Á¦6Àå Á¡µµº° ºñÁö´Ï½º ºÐ¼®

  • OTC ¾È±¸°ÇÁ¶Áõ¿ë Á¡¾È¾à ½ÃÀå : Á¡µµ º¯µ¿ ºÐ¼®, 2022³â ¹× 2030³â
  • ÀúÁ¡µµ
  • °íÁ¡µµ

Á¦7Àå À¯Åë ä³Îº° ºñÁö´Ï½º ºÐ¼®

  • OTC ¾È±¸°ÇÁ¶Áõ¿ë Á¡¾È¾à ½ÃÀå : À¯Åë ä³Î º¯µ¿ ºÐ¼®, 2022³â ¹× 2030³â
  • µå·°½ºÅä¾î¿Í ½´ÆÛ¸¶ÄÏ
  • ¿Â¶óÀÎ ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ±âŸ

Á¦8Àå Áö¿ªº° ºñÁö´Ï½º ºÐ¼®

  • Áö¿ª ½ÃÀå ÇöȲ
  • ºÏ¹Ì
    • ºÏ¹Ì OTC ¾È±¸°ÇÁ¶Áõ¿ë Á¡¾È¾à ½ÃÀå, 2018-2030³â
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • À¯·´ OTC ¾È±¸°ÇÁ¶Áõ¿ë Á¡¾È¾à ½ÃÀå, 2018-2030³â
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ OTC ¾È±¸°ÇÁ¶Áõ¿ë Á¡¾È¾à ½ÃÀå, 2018-2030³â
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä« OTC ¾È±¸°ÇÁ¶Áõ¿ë Á¡¾È¾à ½ÃÀå, 2018-2030³â
    • ÁÖ¿ä ±¹°¡ µ¿Çâ
    • ±ÔÁ¦ ü°è
    • °æÀï ½Ã³ª¸®¿À
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • MEA OTC ¾È±¸°ÇÁ¶Áõ¿ë Á¡¾È¾à ½ÃÀå, 2018-2030³â
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦9Àå °æÀï »óȲ

  • ±â¾÷ ºÐ·ù
  • Àü·« ¸ÅÇÎ
    • Ãëµæ
    • Çù¾÷
    • »õ·Î¿î Ç÷§Æû ¹ßÇ¥
    • ±âŸ
  • ±â¾÷ °³¿ä¡¤¸®½ºÆ®
    • Rohto Pharmaceutical Co., Ltd.
    • AbbVie, Inc.
    • Johnson &Johnson Services, Inc.
    • Santen Pharmaceutical Co. Ltd.
    • Novartis AG
    • Prestige Consumer Healthcare Inc.
    • Altaire Pharmaceutical Inc.
    • Sentiss Pharma Private Limited
    • Medicom Healthcare Pvt Ltd.
ksm 23.11.01

OTC Dry Eye Drops Market Growth & Trends:

The global OTC dry eye drops market size is expected to reach USD 6.09 billion by 2030, expanding at a CAGR of 7.70% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Key factors that drive the market growth are the rising prevalence of dry eye disease, increasing eyesight strain due to the widespread use of digital devices such as smartphones and computers, and the increasing aging population globally.

Growing health consciousness and awareness of ocular health are expected to drive product demand. Over 750 million people worldwide have both symptoms and clinical signs of dry eyesight, whereas over 600 million are at risk of developing dry eye disease (DED) since they have clinical signs but do not have symptoms, making up a sizeable population of about 1.4 billion people who suffer from symptoms but not clinical signs of DED, thereby driving the demand for OTC dry eye drops in the marketplace.

Furthermore, urbanization and modern lifestyles further contribute to the high prevalence of dry ocular syndrome. Prolonged screen time associated with urban living can lead to reduced blinking frequency and disruption of the tear film, while environmental pollutants in urban areas can irritate eyesight. Moreover, long commutes and various stressors of urban life, including irregular sleep patterns, can negatively impact tear production and overall ocular comfort, fueling the market growth for OTC dry eye drops.

Key participants are engaged in strategies such as agreements, mergers & acquisitions, partnerships, and launches, among others, to expand their global footprint and product portfolio. For instance, in January 2022, Alcon launched the Systane Complete Preservative-Free Lubricant Eye Drops in Europe, with an aim to expand its footprint in the large and fast-growingpreservative-free category of eye drops. Furthermore, in July 2023, TheaLipid was launched by Thea Pharmaceuticals for the treatment of DED, supporting its expansion plans.

OTC Dry Eye Drops Market Report Highlights:

  • In terms of type, the generics segment held the largest revenue share in the market in 2022 and is anticipated to grow at the fastest rate over the forecast period, owing to the cost-effectiveness of generic products
  • Based on product type, with preservatives segment held the largest market revenue share in 2022. Longer shelf life and easier storage play a vital role in contributing to segment growth
  • With regards to viscosity, the low-viscosity segment dominated the market in 2022.Ease of application and rapid relief are projected to boost the segment's growth in the coming years
  • Based on the distribution channel, the retail pharmacies segment led the market in 2022 due to their accessibility and convenience, making it easy for consumers to purchase OTC products such as dry eye drops
  • North America held the largest revenue share in 2022. The presence of well-established market players, a large and diverse patient pool, and the rising geriatric population with increased dry eye susceptibility fuel regional growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Market Definitions
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
      • 3.3.1.1. Increasing prevalence of dry eye syndrome
      • 3.3.1.2. Growing awareness and self-care practices
      • 3.3.1.3. Increasing geriatric population
      • 3.3.1.4. Increasing use of contact lenses
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. Limited efficacy for severe cases
      • 3.3.2.2. Regulatory constraints and quality concerns
  • 3.4. Business Environment Analysis
    • 3.4.1. PESTLE Analysis
    • 3.4.2. Porter's Five Forces Analysis
  • 3.5. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. OTC Dry Eye Drops Market: Type Movement Analysis, 2022 & 2030
  • 4.2. Branded
    • 4.2.1. Branded Market, 2018 - 2030 (USD Million)
  • 4.3. Generics
    • 4.3.1. Generics Market, 2018 - 2030 (USD Million)

Chapter 5. Product Type Business Analysis

  • 5.1. OTC Dry Eye Drops Market: Product Type Movement Analysis, 2022 & 2030
  • 5.2. With Preservatives
    • 5.2.1. With Preservatives Market, 2018 - 2030 (USD Million)
  • 5.3. Preservative Free
    • 5.3.1. Preservative Free Market, 2018 - 2030 (USD Million)

Chapter 6. Viscosity Business Analysis

  • 6.1. OTC Dry Eye Drops Market: Viscosity Movement Analysis, 2022 & 2030
  • 6.2. Low Viscosity
    • 6.2.1. Low Viscosity Market, 2018 - 2030 (USD Million)
  • 6.3. High Viscosity
    • 6.3.1. High Viscosity Market, 2018 - 2030 (USD Million)

Chapter 7. Distribution Channel Business Analysis

  • 7.1. OTC Dry Eye Drops Market: Distribution Channel Movement Analysis, 2022 & 2030
  • 7.2. Drugstores and Supermarkets
    • 7.2.1. Drugstores and Supermarkets Market, 2018 - 2030 (USD Million)
  • 7.3. Online Pharmacies
    • 7.3.1. Online Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.4. Retail Pharmacies
    • 7.4.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.5. Others
    • 7.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Regional Market Snapshot
  • 8.2. North America
    • 8.2.1. North America OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.2.2.2. Key Country Dynamics
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. Competitive Scenario
    • 8.2.3. Canada
      • 8.2.3.1. Canada OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.2.3.2. Key Country Dynamics
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Competitive Scenario
  • 8.3. Europe
    • 8.3.1. Europe OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
    • 8.3.2. Germany
      • 8.3.2.1. Germany OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.3.2.2. Key Country Dynamics
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. Competitive Scenario
    • 8.3.3. UK
      • 8.3.3.1. UK OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.3.3.2. Key Country Dynamics
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Competitive Scenario
    • 8.3.4. France
      • 8.3.4.1. France OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.3.4.2. Key Country Dynamics
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. Competitive Scenario
    • 8.3.5. Italy
      • 8.3.5.1. Italy OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.3.5.2. Key Country Dynamics
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Competitive Scenario
    • 8.3.6. Spain
      • 8.3.6.1. Spain OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.3.6.2. Key Country Dynamics
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Competitive Scenario
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.3.7.2. Key Country Dynamics
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Competitive Scenario
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.3.8.2. Key Country Dynamics
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Competitive Scenario
    • 8.3.9. Norway
      • 8.3.9.1. Norway OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.3.9.2. Key Country Dynamics
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Competitive Scenario
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.4.2.2. Key Country Dynamics
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Competitive Scenario
    • 8.4.3. China
      • 8.4.3.1. China OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.4.3.2. Key Country Dynamics
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Competitive Scenario
    • 8.4.4. India
      • 8.4.4.1. India OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.4.4.2. Key Country Dynamics
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Competitive Scenario
    • 8.4.5. South Korea
      • 8.4.5.1. South Korea OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.4.5.2. Key Country Dynamics
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Competitive Scenario
    • 8.4.6. Australia
      • 8.4.6.1. Australia OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.4.6.2. Key Country Dynamics
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Competitive Scenario
    • 8.4.7. Thailand
      • 8.4.7.1. Thailand OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.4.7.2. Key Country Dynamics
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Competitive Scenario
  • 8.5. Latin America
    • 8.5.1. Latin America OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
    • 8.5.2. Key Country Dynamics
    • 8.5.3. Regulatory Framework
    • 8.5.4. Competitive Scenario
    • 8.5.5. Brazil
      • 8.5.5.1. Brazil OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.5.5.2. Key Country Dynamics
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Competitive Scenario
    • 8.5.6. Mexico
      • 8.5.6.1. Mexico OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.5.6.2. Key Country Dynamics
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Competitive Scenario
    • 8.5.7. Argentina
      • 8.5.7.1. Argentina OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.5.7.2. Key Country Dynamics
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Competitive Scenario
  • 8.6. MEA
    • 8.6.1. MEA OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.6.2.2. Key Country Dynamics
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Competitive Scenario
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Saudi Arabia OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.6.3.2. Key Country Dynamics
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Competitive Scenario
    • 8.6.4. UAE
      • 8.6.4.1. UAE OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.6.4.2. Key Country Dynamics
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Competitive Scenario
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait OTC Dry Eye Drops Market, 2018 - 2030 (USD Million)
      • 8.6.5.2. Key Country Dynamics
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Competitive Scenario

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
    • 9.2.1. Acquisition
    • 9.2.2. Collaborations
    • 9.2.3. New Platform Launches
    • 9.2.4. Others
  • 9.3. Company Profiles/Listing
    • 9.3.1. Rohto Pharmaceutical Co., Ltd.
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Platform Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. AbbVie, Inc.
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Platform Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Johnson & Johnson Services, Inc.
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Platform Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Santen Pharmaceutical Co. Ltd.
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Platform Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Novartis AG
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Platform Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Prestige Consumer Healthcare Inc.
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Platform Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Altaire Pharmaceutical Inc.
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Platform Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Sentiss Pharma Private Limited
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Platform Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Medicom Healthcare Pvt Ltd.
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Platform Benchmarking
      • 9.3.9.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦